Press release
Tenosynovial Giant Cell Tumors Market Size, Epidemiology, Pipeline Therapies and Companies by DelveInsight | Daiichi Sankyo, Five Prime Therapeutics, Deciphera Pharmaceuticals, Novartis and Others
Tenosynovial Giant Cell Tumors Market
DelveInsight's "Tenosynovial Giant Cell Tumors (TSGCTs) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tenosynovial Giant Cell Tumors (TSGCTs), historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors (TSGCTs) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To know more about Tenosynovial Giant Cell Tumors Market Report, Click Here: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of Tenosynovial Giant Cell Tumors Market:
• According to the National Organization for Rare Disorders (2022), Tenosynovial Giant Cell Tumors mainly affect individuals between 25-50 years of age, with a median age of diagnosis of 40. However, these tumors can affect the elderly and younger children as well. There is a slight female preponderance in localized TGCT; however, in diffuse TGCT, there is no sex predilection.
• According to the National Institute For Health and Care Excellence (2022), TGCT mainly affects adults between 20 and 50 years. The annual incidence has been estimated at between 11 and 43 in 1,000,0001. This would equate to between approximately 600 and 2400 cases per year in England.
• Localized forms predominate in the digits (85%), near to the synovial sheaths or interphalangeal joints, and more often on the palmar than the dorsal side. Other locations comprise wrist, foot and ankle, knee and, very rarely, hip or elbow. The intra-articular localized form are mostly frequent in the knee (Gouin & Noailles, 2017).
• According to DelveInsight's analysis, there are more cases of Localized TGCTs in females than males.
To know more facts about Tenosynovial Giant Cell Tumors, Request sample here: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Tenosynovial Giant Cell Tumors Market Report
• The report covers the descriptive overview of Tenosynovial Giant Cell Tumors (TSGCTs), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Tenosynovial Giant Cell Tumors (TSGCTs) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Tenosynovial Giant Cell Tumors (TSGCTs) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Tenosynovial Giant Cell Tumors (TSGCTs) market.
Know more about the scope of the Tenosynovial Giant Cell Tumors report: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the Tenosynovial Giant Cell Tumors Companies
• Daiichi Sankyo
• Five Prime Therapeutics
• Deciphera Pharmaceuticals
• Novartis
• And Many Others
Know more about the Tenosynovial Giant Cell Tumors Companies and Pipeline: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents:
1. Key Insights
2. Executive Summary of Tenosynovial Giant Cell Tumors (TSGCTs)
3. Competitive Intelligence Analysis for Tenosynovial Giant Cell Tumors (TSGCTs)
4. Tenosynovial Giant Cell Tumors (TSGCTs): Market Overview at a Glance
5. Tenosynovial Giant Cell Tumors (TSGCTs): Disease Background and Overview
6. Patient Journey
7. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Tenosynovial Giant Cell Tumors (TSGCTs) Treatment
11. Marketed Products
12. Emerging Therapies
13. Tenosynovial Giant Cell Tumors (TSGCTs): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Tenosynovial Giant Cell Tumors (TSGCTs)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. Publisher Capabilities
22. Disclaimer
Request for Detailed TOC: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Other Trending Reports:
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Onycholysis Market: https://www.delveinsight.com/report-store/onycholysis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• France Healthcare Outlook Report: https://www.delveinsight.com/report-store/france-healthcare-outlook-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Italy Healthcare Outlook Report: https://www.delveinsight.com/report-store/italy-healthcare-outlook-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact us:
Ankit Nigam
info@delveinsight.com
+19193216187
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life science. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tenosynovial Giant Cell Tumors Market Size, Epidemiology, Pipeline Therapies and Companies by DelveInsight | Daiichi Sankyo, Five Prime Therapeutics, Deciphera Pharmaceuticals, Novartis and Others here
News-ID: 2666311 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Tenosynovial
Tenosynovial Giant Cell Tumors Pipeline Outlook 2025: Clinical Trial Studies, EM …
DelveInsight's, "Tenosynovial Giant Cell Tumors Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial Giant Cell Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Tenosynovial Giant Cell Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Tenosynovial Giant Cell Tumors Market: Epidemiology, Pipeline Products, and Comp …
Daiichi Sankyo's TURALIO is the only FDA-approved Tenosynovial Giant Cell Tumors therapy. However, a significant number of patients still use an off-label treatment like imatinib due to TURALIO's problematic safety and tolerability profile.
Tenosynovial Giant Cell Tumors emerging therapies such as TURALIO (pexidartinib), Vimseltinib (DCC-3014), and others are expected to boost the Tenosynovial Giant Cell Tumors Market in the upcoming years.
DelveInsight has launched a new report on "Tenosynovial Giant Cell Tumors…
Tenosynovial Giant Cell Tumors Market: Analysis of Epidemiology, Pipeline Produc …
Tenosynovial Giant Cell Tumors emerging therapies such as TURALIO (pexidartinib), Vimseltinib (DCC-3014), and others are expected to boost the Tenosynovial Giant Cell Tumors Market in the upcoming years.
DelveInsight has launched a new report on "Tenosynovial Giant Cell Tumors - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends…
Tenosynovial Giant Cell Tumors Treatment Market 2034: EMA, PDMA, FDA Approval, C …
Tenosynovial Giant Cell Tumors Companies are Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others.
(Albany, USA) DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4…
Tenosynovial Giant Cell Tumors Market to Exhibit Substantial Growth Rate During …
As per DelveInsight, the Tenosynovial Giant Cell Tumors therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of TSGCTs and the launch of the emerging drug in the 7MM.
Companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others, are actively…
Tenosynovial Giant Cell Tumors Market to Exhibit Substantial Growth Rate During …
As per DelveInsight, the Tenosynovial Giant Cell Tumors therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of TSGCTs and the launch of the emerging drug in the 7MM.
Companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others, are actively…
